Precision Control of Gene Regulation through Synthetic Promoters
ARM Cell & Gene Therapy Investor Day Presentation
David Venables presented at this year's ARM Cell & Gene Therapy Investor Day. View his presentation for Synpromics' latest updates.
Catch up on Synpromics' latest news in our December 2018 newsletter.
David Venables and Michael Roberts joined Gbola Amusa, Head of Healthcare Research at Chardan, to explore the applications of synthetic biology in promoter design, the role of bioinformatics and the potential of synthetic promoters in gene medicines. Watch the webinar here.
'To win at gene therapy, companies pick viruses with production credentials' - Cormac Sheridan. Read the article.
Sarah Haecker Meeks and Michael Roberts discuss 'Accelerating the development of Liver Gene Medicines'. Read the article.
Synpromics features in the 'Top Ten Biotechs in Scotland to Watch Out For' - Jonathan Smith. View the full list.
Sypromics features in 'Vision Scotland: Healthy Options in a new age of enlightenment" - Sandra Dick. Read the article.
'Some science and some serendipity' – Jack Leeming interviews Flavia Scialpi. Read the interview.
Medical Expo e-Magazine
'AI Could Revolutionize Gene Therapy' - Daniel Allen speaks to Dr Michael Roberts. Read the article.
Karen Tkach Tuzman discusses synthetic promoters with Dr Michael Roberts - "Synthetic Expressions'. Read the article.
Innovations in Pharmaceutical Technology
'Going Forward' Dr Michael Roberts shares insights into the next generation of gene therapy. Read the article.
'Is gene therapy coming of age?' - Dr Michael Roberts. Read the article.
Inducible synthetic promoters for the production of gene therapy viral vectors
The CSO describes the importance of leveraging functional genomics for synthetic promoter design
The scope of this chapter is to examine how advances in the field of Bioinformatics can be applied in the development of improved therapeutic strategies. In particular, we focus on how algorithms designed to unravel complex gene regulatory networks can then be used in the design of synthetic gene promoters that can be subsequently incorporated in novel gene transfer vectors to promote safer and more efficient expression of therapeutic genes for the treatment of various pathological conditions. Read More…